Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials

Iaconelli, A. et al. (2023) Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials. European Journal of Heart Failure, 25(7), pp. 1170-1175. (doi: 10.1002/ejhf.2911) (PMID:37211964)

Abstract

Background and aims: Coronary artery disease (CAD) is a common cause of heart failure (HF). Whether coronary revascularisation improves outcomes in patients with HF receiving guideline-recommended pharmacological therapy (GRPT) remains uncertain; therefore, we conducted a systematic review and meta-analysis of relevant randomized controlled trials (RCTs). Methods: We searched in public databases for RCTs published between 1st January 2001 and 22nd November 2022, investigating the effects of coronary revascularisation on morbidity and mortality in patients with chronic HF due to CAD. All-cause mortality was the primary outcome. Results: We included five RCTs that enrolled, altogether, 2,842 patients (most aged <65 years; 85% men; 67% with left ventricular ejection fraction ≤35%). Overall, compared to medical therapy alone, coronary revascularisation was associated with a lower risk of all-cause mortality (HR 0.88 [95% CI, 0.79-0.99]; p=0.0278) and cardiovascular mortality (HR 0.80 [95% CI, 0.70-0.93]; p=0.0024) but not the composite of hospitalisation for HF or all-cause mortality (HR 0.87 [95% CI, 0.74-1.01]; p=0.0728). There were insufficient data to show whether the effect of CABG or PCI were similar or differed. Conclusions: For patients with chronic HF and CAD enrolled in RCTs, the effect of coronary revascularization on all-cause mortality was statistically significant but neither substantial (HR 0.88) nor robust (upper 95% CI close to 1.0). RCTs were not blinded, which may bias reporting of the cause-specific reasons for hospitalization and mortality. Further trials are required to determine which patients with HF and CAD obtain a substantial benefit from coronary revascularization by either CABG or PCI.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: iaconelli, Dr antonio and Maffia, Professor Pasquale and CAIAZZO, Miss ELISABETTA and Cleland, Professor John and Rezig, Asma Oumkaltoum and Pellicori, Dr Pierpaolo
• Authors: Iaconelli, A., Pellicori, P., Dolce, P., Busti, M., Ruggio, A., Aspromonte, N., D'Amario, D., Galli, M., Princi, G., Caiazzo, E., Rezig, A. O.M., Maffia, P., Pecorini, G., Crea, F., and Cleland, J. G.F.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health; College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Research Centre: College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
• Journal Name: European Journal of Heart Failure
• Publisher: Wiley
• ISSN: 1388-9842
• ISSN (Online): 1879-0844
• Published Online: 22 May 2023
• Copyright Holders: Copyright © 2023 The Authors
• First Published: First published in European Journal of Heart Failure 25(7):1170-1175
• Publisher Policy: Reproduced under a Creative Commons License